Retrospective Observational Study of Atopic Dermatitis Patient Treated with Tralokinumab in Japanese Real-world Practice

Retrospective Observational Study of Atopic Dermatitis Patient Treated with Tralokinumab in Japanese Real-world Practice - A retrospective analysis of tralokinumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056931

Enrollment

125

Registered

2025-02-10

Start date

2025-02-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients treated with tralokinumab for the treatment of AD which is inadequately responsive to conventional therapies Patients with medical records of at least 16 weeks or more after starting tralokinumab treatment

Exclusion criteria

Exclusion criteria: Cases where tralokinumab was clearly used outside its approved indications. Patients with prior experience participating in clinical trials for tralokinumab. Patients who have refused to participate in this study (i.e., refused the use of their medical records). The opportunity for research subjects to refuse the use of their medical records in this study (opt-out) will be ensured.

Design outcomes

Primary

Measure	Time frame
Distribution of IGA scores from the start of Tralokinumab administration at16 weeks	—

Countries

Japan

Contacts

Public ContactMotohiro Honda

EBC&M LLC Clinical Division

crs5-info@ebc-m.com0364353833

Outcome results